The expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.

Key Takeaways on Evolving Bladder Cancer Treatment Landscape

Videos

The panel discusses the Large Urology Group Practice Association and provides insights on collaborative care approaches in bladder cancer.

Approach to Collaborative Care in Bladder Cancer

Bladder cancer specialists discuss enfortumab vedotin and the role of antibody-drug conjugates in the treatment landscape.

Enfortumab Vedotin and the Role of ADCs in Bladder Cancer

The expert panel reviews highlights from ESMO 2023 and discusses ongoing developments in the treatment landscape for bladder cancer.

Bladder Cancer: Highlights from ESMO 2023 and Ongoing Developments

Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.

Bladder Cancer: Treatment Options and Managing Adverse Effects

The panel discusses strategies for monitoring patients with non–muscle invasive bladder cancer and the potential role of biomarkers.

Monitoring Patients With NMIBC

Expert perspectives on treatment options available for patients with bladder cancer and the role of trimodal therapy.

Treatment Considerations and Role of Trimodal Therapy in Bladder Cancer

A panel of experts on bladder cancer provide an overview of the stratification, natural history, and treatment of bladder cancer.

Overview of Non–Muscle Invasive Bladder Cancer (NMIBC)

Axel Merseburger, MD, PhD, chairman, Clinic of Urology, University Hospital Schleswig-Holstein in Lübeck, Germany, discusses results from the phase 3b PRESIDE trial (NCT02288247) in metastatic castration-resistant prostate cancer (mCRPC). 

The randomized study investigated the efficacy of continuing enzalutamide (Xtandi) plus androgen deprivation therapy (ADT) with docetaxel and prednisolone in chemotherapy-naïve patients with mCRPC who had progressed on enzalutamide plus ADT. All enrolled patients were administered 160 mg of enzalutamide plus ADT in period 1 of the trial. Patients who experienced a change in prostate-specific antigen response of at least 50% from baseline to week 13 and subsequent disease progression were then randomized to receive enzalutamide or placebo, plus 75 mg/m2 of docetaxel, 10 mg of prednisolone, and ADT.

The continuation of enzalutamide produced a statistically significant advantage in progression-free survival (PFS) compared with placebo, meeting the trial’s primary end point, Merseburger says. The hazard ratio for PFS was 0.72 in favor of the enzalutamide combination with a corresponding 

Axel Merseburger, MD, PhD, discusses results from the phase 3b PRESIDE trial in metastatic castration-resistant prostate cancer. 


Axel Merseburger, MD, PhD

Articles